Amyotrophic lateral sclerosis is a fatal CNS neurodegenerative disease. Despite intensive
research, current management of amyotrophic lateral sclerosis remains suboptimal from …

Motor neuron disease can be viewed as an umbrella term describing a heterogeneous
group of conditions, all of which are relentlessly progressive and ultimately fatal. The …

The availability of disease modifying therapies for spinal muscular atrophy (SMA) has
created an urgent need to identify clinically meaningful biomarkers. Biomarkers present a …

Summary Background CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective
agent that enhances intracellular energy metabolism and reduces oxidative stress. The …

Amyotrophic lateral sclerosis (ALS) encompasses a heterogeneous group of phenotypes
with different progression rates, varying degree of extra-motor involvement and divergent …

Thoughtful clinical trial design is critical for efficient therapeutic development, particularly in
the field of amyotrophic lateral sclerosis (ALS), where trials often aim to detect modest …

Although the past two decades have produced exciting discoveries in the genetics and
pathology of amyotrophic lateral sclerosis (ALS), progress in developing an effective therapy …

Objective There is still insufficient knowledge about natural history in adult spinal muscular
atrophy, thus valid markers for treatment and disease monitoring are urgently needed …

Objective Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease
that leads to inexorable motor decline and a median survival of three years from symptom …

Objectives MUNIX (motor unit number index), derived from the compound muscle action
potential (CMAP) and surface EMG interference pattern (SIP) has become popular as a …